Cognition Therapeutics Inc. (CGTX) is a clinical stage, biopharmaceutical company dedicated to improving the lives of patients with neurodegenerative disorders. The company is primarily focused on Alzheimer's disease, a devastating condition that has yet to find any long-lasting treatment or cure. CGTX’s mission revolves around halting the progression of neurodegenerative diseases, thereby providing a quality life for patients while also reducing the healthcare burden on families, and society as a whole.
Founded in 2007 and headquartered in Pittsburgh, Pennsylvania, the company leverages an internal and external network of scientific, clinical and business expertise, driving its dedication to bettering human health. It's an entrepreneurial venture that adopts a rigorous, science-led, and patient-focused approach to discover and develop novel therapeutics.
One of its leading drug candidates is CT1812, a proprietary, disease-modifying therapeutic designed to halt the toxic cascades induced by Aβo. The first-in-patient clinical proof of mechanism study (Elayta) for CT1812 is currently being conducted across several hospitals and clinics in the US. Findings from this study have shown that CT1812 can decrease brain amyloid levels, improve memory and cognition, and stabilize daily function in Alzheimer's patients.
CT1812 is not CGTX's sole focus. The company has other potent clinical and pre-clinical product candidates within its pipeline, including CT831 for dementia with Lewy bodies, a progressive brain disorder, and CT854 for PTSD-related cognitive impairment. CGTX believes the combination of its unique research approach, deep clinical development expertise, and strong IP protection places it in the best position to deliver breakthrough therapies for patients suffering from debilitating neurological disorders.
The company listed on the NASDAQ stock market, under the ticker symbol of "CGTX", on January 29, 2021. CGTX operates as a full-blown pharmaceutical company, with duties covering clinical development, intellectual property, finance, human resources, marketing, regulatory interactions, and sales. All these are conducted to the highest standards, with patient welfare and interests at the heart of their operations.
Their dedication to groundbreaking research in the field of Alzheimer's and other neurodegenerative disorders makes them a company poised to contribute significantly to medical science and society. Looking forward, CGTX continues to strive for new discovery and development, with patient benefit the ultimate goal. Their work represents hope for millions of people living with neurodegenerative disorders worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
HC Wainwright has increased its Q3 2026 EPS estimate for Cognition Therapeutics (NASDAQ:CGTX) to a loss of $0.06 per share from a previous estimate of a $0.07 loss, maintaining a "Buy" rating. This update comes after Cognition Therapeutics reported a Q2 loss of $0.04 per share, surpassing analyst estimates. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $3.33, though analyst opinions are mixed.
Brookline Capital Markets has increased its FY2026 EPS estimate for Cognition Therapeutics (NASDAQ:CGTX) to a loss of $0.42 per share, an improvement from their previous forecast of a $0.44 loss, though still below the consensus of a $0.34 loss. The company recently reported a quarterly loss of $0.04 per share, surpassing analyst expectations. Despite a slight dip in share price, analysts maintain a "Moderate Buy" rating with an average target of $3.33, and institutional investors hold a significant stake in the company.
Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $3.33.
Cognition Therapeutics reported its financial results for the second quarter of 2026, highlighting progress in its clinical and corporate priorities, particularly for its lead candidate zervimesine. The company held discussions with the FDA for a Phase 3 trial in dementia with Lewy bodies (DLB) psychosis and secured a new patent extending protection through 2045. Cognition Therapeutics ended the quarter with $34.8 million in cash, projecting funds into Q4 2027, and reported a reduced net loss compared to the previous year.